# Pharmaceutical Industry

The 30,000-Yuan Red Line: China’s Healthcare Sector Reels Under Strict New Anti-Bribery Rules

China has introduced a strict new judicial interpretation lowering the criminal prosecution threshold for healthcare bribery to 30,000 RMB, triggering widespread panic among doctors and pharmaceutical firms. The move targets both public and private sectors, holding companies liable for employee misconduct and signaling an end to the era of relationship-based medical sales.